Scarica l'app Stockscreener
1.97
2.07%
0.04
Dopo l'orario di chiusura:
1.95
-0.02
-1.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMRA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.93
Aprire:
$2.055
Volume 24 ore:
30,726
Relative Volume:
1.41
Capitalizzazione di mercato:
$6.09M
Reddito:
$4.33M
Utile/perdita netta:
$-4.17M
Rapporto P/E:
-1.3175
EPS:
-1.4953
Flusso di cassa netto:
$-3.19M
1 W Prestazione:
-2.48%
1M Prestazione:
-15.81%
6M Prestazione:
-17.57%
1 anno Prestazione:
-39.57%
Intervallo 1D:
$1.9568
$2.11
Intervallo di 1 settimana:
$1.905
$2.18
Portata 52W:
$1.8664
$4.60
Biomerica Inc Stock (BMRA) Company Profile
Nome
Biomerica Inc
Settore
Industria
Telefono
(949) 379-2875
Indirizzo
17571 VON KARMAN AVENUE, IRVINE, CA
Compare BMRA vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRA
Biomerica Inc
|
1.97 | 6.18M | 4.33M | -4.17M | -3.19M | -1.4953 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Biomerica Inc Stock (BMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-11-10 | Iniziato | Colliers Securities | Buy |
| 2018-01-04 | Iniziato | B. Riley FBR, Inc. | Buy |
Biomerica Inc Borsa (BMRA) Ultime notizie
Biomerica (BMRA) Slips Slightly to $2.05; Near Key Support Amid Quiet TradingDark Pool Volume - newsline.com
Biomerica (BMRA) Edges Lower, Testing Key Support at $1.95ETF Liquidity - newsline.com
Biomerica (BMRA) Edges Higher as Stock Holds Above Key Support LevelIV Contraction - newsline.com
BMRA Q1 2026 Earnings: Net Loss of $0.44 per Share; Stock Declines 0.92%Analyst Consensus Shift - newsline.com
Biomerica (BMRA) Slides Slightly as Stock Approaches Key Support LevelIceberg Order - newsline.com
Biomerica (BMRA) Q1 2026 Earnings: Narrowing Loss Amid Ongoing Operational ChallengesReturn On Capital - newsline.com
Biomerica, Inc. Announces $500,000 Securities Purchase Agreement and Secured Promissory Note – Form 8-K Filing, May 29, 2026 – Minichart - Minichart
Biomerica Enters Related-Party Deal to Boost Liquidity - TipRanks
Biomerica to Sell 6% Diagnosis Stake for $500,000; Issues 8% Note Pending Transfer - TradingView
Biomerica (BMRA) sells 6% Diagnosis S.A. stake to CEO-affiliated buyers - Stock Titan
Biomerica Inc. (BMRA) Sees Modest Gain as Shares Test Key ResistanceDip Buy Trade - newsline.com
BMRA Q1 2026 Earnings: Operating Loss Widens to $0.44 per Share as Pre-Revenue Biotech Advances Pipeline - newsline.com
Biomerica secures USD 1.75M contract for IVD diagnostic development - Medical Buyer
BMRA Stock Price, Quote & Chart | BIOMERICA INC (NASDAQ:BMRA) - ChartMill
Biomerica Inc. Awarded $1.75 Million Contract for IVD Product Development - geneonline.com
Biomerica (BMRA) Secures Master Services Agreement for Diagnosti - GuruFocus
Biomerica Inc. (BMRA) Holds Near Support Amid Modest PullbackBeta Neutral Pair - The Legal Advocate
Biomerica Wins $1.75M Contract to Develop Diagnostic Tests - Orange County Business Journal
Biomerica signs contract development deal worth over $1.75M By Investing.com - Investing.com Canada
Biomerica lands $1.75 million CDMO master services agreement for IVD diagnostic development - marketscreener.com
Biomerica signs contract development deal worth over $1.75M - Investing.com
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development - The Manila Times
Undisclosed $1.75M lab deal taps Biomerica’s diagnostic test expertise - Stock Titan
Biomerica Q1 2026 Earnings: Net Loss of $0.44 Per Share Amid Lack of Revenue DisclosureManagement Guidance Update - The Legal Advocate
Biomerica Inc. (BMRA) Q1 2026 Earnings: Negative EPS Persists Amid Pre-Revenue StageEarnings Season Review - The Legal Advocate
BMRA Q1 2026 Earnings: Biomerica Reports Net Loss of $0.44 Per Share Amid Ongoing Development Efforts - Newser
Biomerica (BMRA) Q1 2026 Earnings: Revenue $N/A, Matching ViewsExpert Entry Points - Newser
ConsumerDirect names Gary Lu as chief financial officer - Investing.com UK
ConsumerDirect names Gary Lu as chief financial officer By Investing.com - Investing.com South Africa
ConsumerDirect adds new CFO to scale its subscription business - Stock Titan
Biomerica (BMRA) Stock Analysis: Falls -3.85%, Watching $2.14 2026-05-18Most Watched Stocks - newser.com
Should You Sell Biomerica (BMRA) After -2.90% Drop? 2026-05-17Crowd Sentiment Stocks - Newser
TradingKey - TradingKey
What Biomerica (BMRA) subscription metrics reveal about retention | BMRA Q1 2026: Biomerica Posts Wider Loss Amid Cost PressureCatalyst Event - Newser
BMRA | BIOMERICA INC Insider Trading - Quiver Quantitative
What nobody tells you about Biomerica (BMRA) stock (Smart Money Outflows) 2026-05-08Value ETF - The Legal Advocate
Why are smart money investors paying attention to Biomerica (BMRA)? (On the Radar) 2026-05-07Verified Stock Signals - newser.com
How Biomerica (BMRA) competitive position is evolving (Bullish Momentum) 2026-05-06Social Investment Platform - newser.com
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026 - Weekly Voice
An IBS diet-guided therapy gets a slot at the world's biggest GI meeting - Stock Titan
BMRA (Biomerica) falls 0.47% after reporting Q1 2026 negative EPS of $-0.44 with no available analyst consensus estimates.Cash Flow Report - The Legal Advocate
BMRA (Biomerica Inc.) posts 1.9 percent year-over-year Q1 2026 revenue dip, shares gain 4.27 percent. - Cổng thông tin điện tử tỉnh Lào Cai
BMRA (Biomerica Inc.) slips 0.91% following Q1 2026 earnings release with no available analyst consensus estimates.Hedge Fund Inspired Picks - Xã Thanh Hà
Biomerica Q3 Sales Fall, Net Loss Widens Amid Restructuring - Orange County Business Journal
BMRA Biomerica reports 1.9% year-over-year Q1 2026 revenue decline, shares drop 2.52% in today’s session.Popular Market Picks - Newser
Biomerica (BMRA) Secures Medicare Coverage for inFoods IBS Tests - GuruFocus
Biomerica Inc Azioni (BMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):